2024-511963-28-00CompletedPhase 1
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Jun 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 78 (actual)
- First submitted
- 16 Apr 2024
- Start date
- 19 Dec 2023
- Lead sponsor
- Institut Gustave Roussy
- Diseases
- Colorectal cancer
- EU CT number
- 2024-511963-28-00
- EudraCT number
- 2021-005363-43
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 78
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Leon Berard | Lyon | France | Completed |
| Institut Gustave Roussy | Villejuif | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.